{"id":31865,"date":"2014-09-24T06:58:37","date_gmt":"2014-09-24T10:58:37","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31865"},"modified":"2014-09-24T06:58:37","modified_gmt":"2014-09-24T10:58:37","slug":"tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865","title":{"rendered":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/24\/2014 (wallstreetpr) \u2013\u00a0<strong>Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)<\/strong> has joined a global consortium to conduct an RNA interference (RNAi) pivotal treatment against Ebola in West Africa.<\/p>\n<p style=\"text-align: justify;\"><strong>Prioritized RNAi Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">According to a Globe Newswire <a href=\"http:\/\/finance.yahoo.com\/news\/tekmira-joins-international-consortium-conduct-101000375.html\" target=\"_blank\">article<\/a>, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR), which is a leading developer of RNAi treatment methods, announced the news of the collaboration yesterday. The ISARIC consists of consists of representatives Fondation Merieux, Medecins Sans Frontieres and the World Health Organization. The Wellcome Trust has awarded 3.2 million pounds to the consortium to fund the program. The award covers funds need in the development of therapeutics and establishment of an operational clinical trials base in two or more centers for Ebola Virus Disease treatments in West Africa. In this regards, RNAi has been considered as priority evaluation therapeutic. It is expected that clinical trials at the consortium funded centers will be based on RNAi therapies.<\/p>\n<p style=\"text-align: justify;\">Tekmira\u2019s President and Chief Executive Officer, Dr. Murray, said that the company is gratified with the consortium\u2019s decision of choosing RNAi as the priority investigational therapeutic in the matter. He addressed the seriousness of the ongoing crisis regarding public health in Africa. He also commended Wellcome Trust for its leadership in contributing the needed funds to initiate and expedite the much-needed initiative.<\/p>\n<p style=\"text-align: justify;\"><strong>Tekmira\u2019s Proposal <\/strong><\/p>\n<p style=\"text-align: justify;\">Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) seeks to develop an RNAi-based product that will specifically target at the viral variant that is responsible for Ebola outbreak. The genetic sequence for the variant is also available now, which make it possible for Tekmira\u2019s product to precisely match the sequence of the infectious agents. This is amongst the most significant features of RNAi treatment.<\/p>\n<p style=\"text-align: justify;\">Dr. Murray also added that Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) is working to create appropriate clinical, as well as regulatory framework for the proposed utilization of investigational treatment options in the Ebola stricken country. He acknowledged that the initiative is a chief contributor in achieving the goal. However, he also highlighted that there are any unanswered and complex decisions that still need to catered to in completely implementing the unique and novel clinical trial platform. He said that he could give no immediate assurance that the consortium will choose Tekmira\u2019s product for the clinical trials at Africa.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/24\/2014 (wallstreetpr) \u2013\u00a0Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) has joined a global consortium to conduct an RNA interference (RNAi) pivotal treatment against Ebola in West [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":18049,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[9573,4911,4910],"stock_ticker":[],"class_list":["post-31865","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-dr-murray","tag-nasdaqtkmr","tag-tekmira-pharmaceuticals-corporation-nasdaqtkmr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/24\/2014 (wallstreetpr) \u2013\u00a0Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) has joined a global consortium to conduct an RNA interference (RNAi) pivotal treatment against Ebola in West [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-24T10:58:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"168\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak\",\"datePublished\":\"2014-09-24T10:58:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\"},\"wordCount\":387,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg\",\"keywords\":[\"Dr. Murray\",\"NASDAQ:TKMR\",\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\",\"name\":\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg\",\"datePublished\":\"2014-09-24T10:58:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg\",\"width\":300,\"height\":168},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865","og_locale":"en_US","og_type":"article","og_title":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak - Wall Street PR","og_description":"Boston, MA 09\/24\/2014 (wallstreetpr) \u2013\u00a0Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) has joined a global consortium to conduct an RNA interference (RNAi) pivotal treatment against Ebola in West [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-24T10:58:37+00:00","og_image":[{"width":300,"height":168,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak","datePublished":"2014-09-24T10:58:37+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865"},"wordCount":387,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg","keywords":["Dr. Murray","NASDAQ:TKMR","Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865","url":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865","name":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg","datePublished":"2014-09-24T10:58:37+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Tekmira-Pharmaceuticals-Corporation.jpg","width":300,"height":168},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/tekmira-pharmaceuticals-corporation-nasdaqtkmrs-rnai-based-therapeutic-approach-to-fight-ebola-outbreak-31865#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)\u2019s RNAi Based Therapeutic Approach To Fight Ebola Outbreak"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31865"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31865\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/18049"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31865"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31865"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}